Currently, both the American Urological Association and the American Society of Clinical Oncology guidelines state that 68 Ga-PSMA PET/CT and 18F-PSMA PET/CT can be indicated for patients with PCa at high risk for metastatic disease [44, 73]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.